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ABSTRACT
Integrating Care: Evaluation of a Hepatitis C Clinic Co-located with Harm Reduction and
Addiction Treatment Programs in a Rural Clinic
Susan R. McKenrick, MSN, APRN, FNP-BC
Background: West Virginia (WV) is second in the nation for cases of Hepatitis C Virus (HCV)
per capita – meaning more than 24,000 residents are living with HCV. Most new cases are in
young persons who inject drugs (PWID). However, the no-call, no-show rate for HCV patients
coming to clinics in Morgantown is about 50%, indicating the need to do a better job engaging
them in care. Literature suggests that integrating HCV clinics with harm reduction and addiction
treatment programs increases uptake of HCV treatment.
Objective: The overall objective was to establish an integrated HCV clinic where harm
reduction and addiction treatment programs are offered to promote uptake of curative treatment
by decreasing the number of no-call/no-show occurrences.
Methods: A 12-week pilot study was planned with three aims for evaluation: 1) establish the
clinic and evaluate rollout with an educational presentation pre/post-test and staff satisfaction
survey followed by an implementation/feasibility survey near the end of the pilot 2) track and
analyze the number of appointments made and kept using an Excel log to compare with other
local clinics’ no-call/no-show rates 3) discover why patients historically have not kept
appointments by use of a questionnaire.
Results: Staff knowledge was significantly increased; the clinic was started; and staff
satisfaction questionnaires returned exclusively positive results, as did implementation/feasibility
follow-up surveys. There was a 10% decrease in the no-call/no-show rate. However, a national
pandemic and seasonal constraint may have affected enrollment, leaving only one patient eligible
to complete the survey.
Discussion: While the clinic startup was successful, clinic attendance was low and reasons for
lack of patient engagement remain largely unknown. However, the clinic is poised to further
explore reasons for lack of engagement to halt the rising rate of HCV transmission in WV.
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Integrating Care: Evaluation of a Hepatitis C Clinic Co-located with Harm Reduction and
Addiction Treatment Programs in a Rural Clinic
The World Health Organization (WHO, 2017) has called for the worldwide elimination
of Hepatitis C Virus (HCV) by 2030. Unfortunately, according to the Centers for Disease
Control (CDC, 2019), the number of HCV cases in Appalachia, and specifically in West Virginia
(WV), continues to climb as sequela to the current opioid epidemic that still has a firm grip in
this state. Most new cases of HCV are in young people who inject drugs (PWID) – in particular,
those who share needles with infected people (CDC). The problem is further complicated by the
lack of HCV patient engagement in disease treatment. Anecdotal evidence from an HCV clinic
held for four hours weekly in a local health department suggests a no-call, no-show rate of about
50% (personal communication, April 2019), and a clinic held in the Infectious Disease
Department of a nearby university affiliated hospital, reports a 70% no-show rate for new
patients and a 30% no-show rate for follow-up visits (K. Burner, personal communication, July
20, 2019). WV will only be able to meet the WHO’s challenge for elimination of HCV by 2030
if providers and clinics implement a model of care that engages patients for HCV treatment and
follow-up.
Background
HCV is a bloodborne virus that can cause systemic problems such as fatigue, coronary
artery disease, endocrine diseases, depression, and more, as well as eventual liver damage that
can lead to liver failure requiring transplantation, cancer, and death, according to the American
Association for the Study of Liver Disease-Infectious Disease Society of America (AASLDIDSA, 2017). Because many of these symptoms are vague and not specific to any one disease,
HCV often goes unrecognized and, thus, untreated – it has been dubbed “the silent killer”
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(AASLD-IDSA, 2017). According to the WHO (2017) there are an estimated 71 million persons
globally living with chronic HCV infections. It is estimated that 2.4 million people are infected
with HCV in the United States (US; Hofmeister et al., 2019). And, although only 3,216 cases of
acute (or newly infected) HCV were reported to the CDC for the US in 2017, given that many do
not have symptoms, the estimates of actual number of acute HCV cases was closer to 44,700
(CDC, 2019). It is worth noting here that, according to the CDC, up to 50% of acute infections
will resolve spontaneously, without treatment. Most significant to WV is that between 2013 and
2017, the rate of HCV in WV nearly doubled – from 3 .1 to 5.6 per 100,000 residents – making
WV currently highest in the nation for new cases per capita (CDC).
A report by the National Viral Hepatitis Roundtable (NVHR, 2019) reveals that
approximately 20,600 West Virginians are chronically infected with HCV and the population at
greatest risk is young people who inject drugs (NVHR). Because there is stigma attached to
PWID, there is also to HCV, as well as fear of being reported to authorities for using illegal
substances. Many of those using injection drugs are either uninsured or have Medicaid as their
primary insurance (NVHR) making it difficult, if not impossible, to obtain treatment for their
illness. Homelessness and lack of steady employment further complicate their situations. Also
complicating treatment and cure are the restrictions imposed by WV Medicaid (which influences
the policies of many commercial insurers) including a 3-month sobriety requirement and that the
prescriber for the curative medications must be a specialist such as gastroenterology, infectious
disease, or hepatology (NVHR). Until October 1, 2019, a liver fibrosis score of F2 or greater
(indicating liver damage had already occurred) was also a requirement to approve treatment- that
restriction has been removed (State Of WV Department Of Health and Human Resources
[WVDHHR]; Bureau For Medical Services, 2019). The cost of the oral direct acting antiviral
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(DAAs), medication which can cure HCV, begins at around $20,000 (NVHR) for the course of
treatment. It is not feasible for most of the affected population to pay out-of-pocket for curative
treatment. Co-pays for office visits and lab/radiology studies can also be cost-prohibitive.
Reported WV Medicaid costs for treating HCV totaled more than $27 million between 2014 and
2016 (WVDHHR, 2019).
Problem Statement
Worldwide elimination of HCV by 2030 is a WHO goal (WHO, 2017); but, with
appointment no-call, no-show rates at HCV clinics in Morgantown ranging from 30 – 70%, and
approximately 20,600 West Virginians needing HCV treatment, it is time for healthcare
providers in WV to change how this population is reached to meet their needs more effectively.
Significance of the Problem
In April of 2019 one of two HCV clinics in Morgantown (staffed by the author) closed
due to an average no-call/no-show rate of 50% that resulted in a low patient volume. Another
clinic in Morgantown associated with infectious disease at West Virginia University (WVU)
hospitals has a higher patient volume – approximately 1000 patients over the past 3.5 years
drawing from WV, OH, and PA – but reports a 70% no-call/no-show rate for first time visits and
30% for follow up visits, which reflects a similar 50% average no show rate (K. Burner, personal
communication, July 20, 2019). However, nearly 20,600 West Virginians with HCV makes
patient engagement an imperative.
Purpose of the Project
The overarching purpose of this project was to increase the number of people living with
chronic HCV who are treated and cured of this potentially life-threatening illness by making care
and treatment more accessible to the population most vulnerable – PWID. Studies have shown
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that by integrating services (HCV, harm reduction, and addiction treatment), patient engagement
is increased (Batchelder et al., 2015; Burton et al., 2019; Butner et al., 2017; Fragomeli &
Weltman, 2015; Treloar et al., 2013), so it follows that the no-call, no-show rate will decrease.
Significance of the Project
Unfortunately, despite the WHO’s (2017) charge, the number of HCV cases in
Appalachia, specifically in WV, continues to climb as sequela to the current opioid epidemic that
still has a firm grip in this state (CDC, 2019; NVHR, 2019). Most new cases of HCV are in
young PWID – particularly those who share needles with infected people (CDC, 2016). This
problem is further complicated by the lack of HCV patient engagement in care for this disease,
as evidenced by the high no-call, no-show rates in two local HCV clinics. WV will only be able
to meet the WHO challenge for elimination of HCV by 2030 if providers and clinics implement
models of care that engage patients for HCV treatment and follow-up.
Review and Synthesis of Literature
An initial non-exhaustive literature review was performed driven by a clinical question
using the Population, Intervention, Comparison, Outcome, Time (PICOT) method (Melnyk &
Fineout-Overholt, 2015): In patients with HCV and coexisting substance use disorder (SUD),
how does integrating and HCV clinic within a clinic offering harm reduction and addiction
treatment programs, compared to separate appointments at another location/clinic increase the
number of patients who engage in care for HCV treatment over 3 months? Using
EbscoHost/CINAHL, Clinical Key, and WVU Libraries “All Databases” function, the Cochrane
database was searched separately, and all included the keywords HCV, Hep C, integrated
treatment, opioid treatment, and HCV treatment. After removing exact duplicates, limiting to the
last 5 years, English language, and peer reviewed – the search yielded 716 results. Inclusion
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criteria was defined as: a) HCV clinics that were integrated within opioid substitution treatment
clinics, b) they were community-based clinics, and c) treatment was with DAAs, and exclusion
criteria defined as a) HCV treatment with older regimens that included ribavirin, interferon, or
other treatment than all-oral DAAs, b) residential treatment settings, c) no integration with harm
reduction or addiction treatment programs were then applied. After reviewing 75 abstracts, 11
applicable publications were included in the review.
Several studies (Batchelder et al., 2015; Burton et al., 2019; Butner et al., 2017; Treloar
et al., 2013) indicated integrated treatment for HCV and drug use is effective in increasing
engagement and follow-up for testing and treatment, citing reasons such as trust in providers,
less stigmatized, and a non-judgmental atmosphere. A retrospective study by Stein et al. (2012)
reported effectiveness of concurrent group treatment (CGT) within a methadone maintenance
program. A systematic review by Pourmarzi et al. (2018) investigating community-based
treatments (including one multidisciplinary model) reported several positive findings, such as
trust in providers and increased accessibility, and suggested integrated services should be further
considered. However, Rance and colleagues (2012) suggest in their study that integration may
further stigmatize this already marginalized population.
Batchelder et al. (2015) studied psychological and behavioral changes in SUD patients
(both current and former) in a primary care clinic (treating HCV) with an integrated methadone
clinic. This qualitative study with 31 participants concluded that an integrated model of care has
the potential to increase patient engagement in care by reducing patient perceptions of stigma
and shame related to HCV and substance use. The study further concluded that the efficacy of
the concept may have been rooted in their group treatment program wherein there was support
for the shared experiences of interferon therapy-related side effects (a possible limitation of the
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study in relation to the current project as only DAA therapy is offered). Another limitation was
convenience sampling. While the purpose of the study was not in alignment with the current
project, the author believes it lends support for HCV clinic integration as a way to increase
engagement in care.
Burton et al. (2019) demonstrated efficacy in integrating HCV care in a residential drug
treatment program for Veterans. The study took place in an academic affiliated VA medical
center with a 15-bed, rolling admission SUD treatment program. The facility serves a crosssection of African American (64%), White (35.4%), and Hispanic (0.6%) Veterans, 54% of
whom are homeless. Many of the clients have psychiatric conditions including depression, posttraumatic stress disorder, and nearly 10% with a significant mental illness such as schizophrenia
or bipolar disorder. The average length of stay was four weeks. In this setting, the SUD clinic
and infectious disease clinics are located near one another, though on different floors of the main
hospital. When SUD patients were discharged, a follow up program was implemented – every
two weeks for those already on HCV treatment, phone calls and letters for those who missed
appointments, and 3-6-month intervals for those waiting to begin treatment. All patients of the
SUD program were offered HCV testing and provided with HCV education (for treatment as
needed and prevention if not infected). The results revealed that uptake in initiation and follow
through to completion of HCV treatment increased with the integrated model of care. Of the 597
patients screened for HCV, 74 were diagnosed with the virus and 53 were appropriate for
treatment. Of these, 48 (77.59%) completed treatment.
There were notable limitations to the Burton et al. (2019) study. First, a threat to internal
validity was the lack of comparative data, making it difficult to determine if there was significant
improvement in uptake of treatment and follow up. Additionally, the study occurred in a VA
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facility where there are no treatment restrictions imposed, as in many state Medicaid programs
(NVHR, 2017), therefore decreasing the ability to generalize results to the other populations,
thus jeopardizing external validity. Despite these limitations, the study supports a clinical shift to
integrating HCV care with addiction treatment to increase patient engagement.
A subsequent search was performed substituting “opioid treatment” with “harm
reduction” in the keywords. Again, using EbscoHost/CINAHL, Clinical Key, and WVU
Libraries “All Databases” function, as well as a separate Cochrane database search, the search
yielded 2,921 results. However, after applying the same inclusion and exclusion criteria, only
three studies were applicable. Two additional studies were included as a result of the
“snowballing” search technique for a total of five more studies included in the final review.
The Brener group (2013) is discussed in further detail below and provided the most
compelling support for connecting HCV treatment and harm reduction. However, in this study,
the harm reduction program was across the street from an HCV clinic and had an established
referral system as a means of engaging patients for the HCV clinic (Brener et al.). Furthermore,
the work actually falls outside the five-year inclusion criteria parameters in an attempt to exclude
studies involving older treatment therapies prior to the advent of all-oral DAAs. Regardless, their
conclusions were enlightening in that an accepting, non-judgmental atmosphere of the clinic
itself that was the noted as key to its success (Brener et al.). Bruggmann and Litwin (2013)
provided a commentary on several models and settings for HCV and concluded that no single
approach is best for all patients with HCV and suggest that there is certainly room for
exploration of innovative models. The work by Kishore et al. (2019) was included for its
perspective on integration with harm reduction programs as key to success and stigma as a
critical barrier to engagement in treatment. Stigma as a barrier is significant in that the primary
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source of transmission is currently shared needle use among PWID, a stigmatized population
(CDC, 2016). Milne et al., (2015) and Morris et al., (2017) both support the concurrent harm
reduction program and HCV clinic model as an effective way to increase patient engagement in
care and curative treatment.
Utilizing mixed methods, the Brener group (2013) evaluated a dedicated HCV clinic
located across the street from a harm reduction program to easily capture referrals from the
program. The clinic was defined as “integrated” and described as “holistic” and included a staff
of nurses, managers, counselors, case workers, general practitioners, academics, a consultant
physician, and a receptionist. In all, 24 staff members and 24 clients participated in the
investigator-led interviews. Through interviews, the researchers discovered that supportive, nonjudgmental relationships between clients and providers were key to the success of the clinic.
Clients and providers articulated that a holistic approach to care was central to improved
outcomes (HCV treatment, symptom management, as well as general health needs). Clients were
enabled to overcome a variety of barriers to care, such as fear of discrimination, feelings of
stigmatization. Unfortunately, an earthquake destroyed the clinic and much of the data of the
quantitative component of the study prior to the completion of the study.
A significant limitation of the work by Brener et al. (2013) is the fact that treatment was
not administered in the clinic; patients were referred to the local hospital for treatment, so
definitions of both internal and external validity are in question as there is no comparison group
to measure improvement against and no statistical results are presented in the work.
Bruggmann and Litwin (2013) reviewed seven effective integrated models of care for
HCV (including integration into addiction treatment and general practice, with community-based
opioid substitution treatment, general practitioner-based models, integrating HCV in secondary
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and tertiary settings, direct observation therapy, and peer-based models). They concluded that
any of these models requires good collaboration of providers, a nonjudgmental attitude among
providers, and an elevated level of acceptance of the patients’ life circumstances. While it was
not a systematic review with statistical analysis, the literature cited supported each model
(several of which are used in the current project).
Using a case study, Milne et al., (2015) describe how an integrated model of care, where
HCV care was co-located with harm reduction and addiction therapy, as well as many other
services, in an inner-city clinic, engendered trusting relationships, which the authors cite as
“central” to enhancing engagement in HCV care and treatment. Over a two-year period, from
2012 through 2014, the clinic grew from 83 to 705 HCV Registry patients, and treated 101
patients with an interferon regimen during the same time period, achieving an average sustained
virologic response (cure) of 81% (Milne et al., 2015). Although a case study, the Milne work
adds more weight to the growing body of literature. In addition, study findings cited support
issues presented in the current project, deeming the Milne group work relevant.
Overall, 10 of the articles reviewed support an integrated model of care and one suggests
that it may actually increase stigma. There is a small, but strong body of literature to support a
shift to an integrated model of care for HCV in the US; however, the search for supporting
literature yielded primarily studies from other countries, particularly the UK and Canada. Even
so, integrated clinics, such as the Evergreen Clinics, a small network of primary care clinics in
Buffalo, NY (Evergreen Health, 2019) that treat SUD as well as HCV do exist. Therefore, it is
reasonable to assume that such a model may be successful in WV, where the number of infected
patients is increasing in direct relation to the state’s opioid epidemic (CDC, 2017).
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In February of 2020, a final literature search was performed using the same keywords and
returning two additional articles appropriate for inclusion related to the topic. While neither is a
research project offering data on integrating HCV care with harm reduction and addiction
treatment, each offers valued information on the subject. Hoj et al. (2019) present a theoretical
framework for study and care of the PWID population. The authors observed that uptake of
treatment had not increased as expected as insurance restrictions to treatment in Canada (which
reflected those still imposed in many states in the US) were removed. They questioned why there
was an apparent gap in care and believed there was a need for “deliberate” theory to support
research and direct the delivery of care to PWID. Interestingly, this group also utilized
“candidacy”, among other theories and frameworks, to shape their own framework; the final
product is built squarely on the theory of candidacy.
An editorial by Marshall et al. (2019) emphasizes the need to change the approach to care
of HCV patients who inject drugs. They suggest not only integrating care in terms of location,
but in terms of care provider – recommending that addiction medicine specialists are well-poised
to facilitate care of HCV in PWID as part of their addiction treatment programs. Although one of
the authors (Treloar) disclosed a conflict of interest (paid speaker’s bureau), the emphasis of this
article is the integrated care model. Both writings support integrated models of care and
treatment and therefore were included in the current review.
Theoretical Frameworks
Two frameworks were chosen to direct this project – Roger’s Diffusion of Innovations
and Candidacy. Rogers (2003) explains that Diffusion of Innovations is about the way a new idea
is communicated to others and perceived by others. According to Rogers, an idea may or may
not necessarily be “new”, as in never thought of before, but it becomes “new” as someone has a
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new awareness of it with a plan to put it into action because the status quo is not working. The
Candidacy framework, as presented by Tookey et al. (2018) speaks to an individual’s sense of
worth or eligibility of treatment for an illness and suggests six stages that may be involved are a)
Identification of candidacy b) Navigation of services c) Permeability of services d) Appearance
at services e) Adjudication by healthcare f) Offers of and resistance to services. How these
frameworks support the project is discussed later.
Project
Evidence-Based Project/Intervention Plan
The project intervention involved strategically integrating an HCV clinic within a local
free primary care clinic, Milan Puskar Health Right (MPHR), that offers both a harm reduction
program and addiction treatment. The overarching goal is to increase engagement in care by
those infected with HCV by locating the clinic in an environment where the population at highest
risk for HCV (PWID) would feel comfortable and welcomed. The hours of operation for the
clinic coincided with the harm reduction program held on Friday afternoons from 1:00 PM until
4:30 PM. The timing offers two benefits: 1) Patients who are already coming for the harm
reduction program are able to schedule appointments for HCV care without making an extra trip
to MPHR and 2) Clients of the harm reduction program who are screened and test positive (via
rapid testing) can be introduced to the provider to establish an immediate therapeutic relationship
which will promote active engagement in care (appointments made and kept.) A Nurse
Practitioner (the author), who has trained extensively in HCV treatment and regularly attends
Project ECHO (Extension for Community Healthcare Outcomes) HCV programming for
continuing support, is the care provider for the clinic. The project received WVU Internal
Review Board (IRB) approval in mid-January. The author had been working closely with key
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staff at MPHR, so the clinic was prepared for almost immediate startup upon IRB approval. The
plan was for the clinic to be held and data collected for 12 weeks. Planned data collection
included a deidentified patient questionnaire to discover themes for lack of engagement in care
(Appendix A) and a deidentified Excel log to track appointments made, kept, cancelled,
rescheduled, and no-call, no-show (Appendix B).
Theoretical Frameworks Discussion
The status quo for HCV treatment is primary care, infectious disease specialty, or
gastroenterology. According to Rogers (2003), there are five phases an innovative plan to change
or improve on the status quo goes through – knowledge, persuasion, decision, implementation,
and confirmation. It was during the “knowledge” phase it became clear that the current HCV
clinic was not well attended at the Health Department and the idea was born to integrate HCV
care with drug addiction treatment. After an initial plan to integrate the clinic into a local
addiction treatment center was found to be unfeasible, the author continued to pursue other
options, leading to the opportunity to integrate HCV care with harm reduction services and
addiction treatment. The “persuasion” phase occurred when a review of literature affirmed
placing the clinic where it would be more easily accessed by those at the highest risk – those who
are injection drug users. The “decision” phase is when the choice to adopt or reject a new idea –
in this case, to adopt – is made. This phase includes buy-in from stakeholders. When the author
approached MPHR key administrative personnel about integrating an HCV Clinic with existing
harm reduction and addiction treatment, the response was unreservedly positive.
“Implementation” is the next phase where a new idea is put into action and outcomes are
measured to see if it is effective. January 17, 2020 was the first day of clinic. Finally, the plan
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itself is confirmed or adopted - either it works and continues, works but needs adjusted, or did
not work and is abandoned.
The Candidacy framework, as presented by Tookey et al. (2018) speaks to an individual’s
sense of worth or eligibility of treatment for an illness and suggests six stages that may be
involved are:
•

Identification of candidacy - is the patient eligible, do they even know they need care?
Do those infected with HCV know there is a cure? HCV has been referred to as a “silent
killer”. Those who are infected often do not realize they have the disease as symptoms
can mimic other diseases and damage to the liver may not be realized for many years
after exposure.

•

Navigation of services - what is their health literacy, can they identify and reach the
proper services? Meeting patients where they are, in a non-threatening environment
where they already access other services will mitigate the problem of poor health literacy
and uncertainty of where to get help for this disease.

•

Permeability of services - do they feel stigmatized or discriminated against, and is the
environment hostile or uninviting? Literature suggests that the stigma of HCV inhibits
use of mainstream services (Treloar et al., 2013). Holding the clinic where they are
already accessing primary care, addiction treatment, and harm reduction services lessens
those feelings.

•

Appearance at services - are patients able to effectively communicate their needs to
providers? HCV symptoms can be vague and mimic other conditions, so patients may
need prompted to elicit an accurate picture of their current health status.
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Adjudication by healthcare - are providers following the care guidelines or does personal
bias interfere? The new DAA medications are expensive and insurers have been
reluctant to provide coverage if patients infected with HCV have no liver damage yet or
are still injecting drugs. Thankfully, many insurers have begun to lift these restrictions,
along with the specialty provider/consult requirement.

•

Offers of and resistance to services - do patients fully understand their treatment options,
the costs, and other treatment-related issues or do they resist offers for testing and
treatment out of fear or lack of knowledge? Patients are not always aware of the newer
oral DAA curative treatments for HCV or they do not realize the side effect profile is not
severe like people they may know had treatment with interferon and/or ribavirin, so they
avoid treatment out of fear of the side effects that they have heard about.

These stages and concepts are the framework for understanding this patient population’s
particular need to be treated for HCV in a non-judgmental, compassionate, friendly environment
where education is provided about how to take care of themselves and their loved ones, prevent
transmission of the disease, and the treatment options that are available to cure the virus.
Feasibility Analysis
With approximately 20,600 West Virginians infected with HCV (NVHR, 2019), more
HCV clinics are needed, not fewer. This quality improvement project was aimed at increasing
patient engagement by establishing an integrated HCV clinic within a local free clinic, coincident
with harm reduction and opioid addiction programs to improve ease of access to HCV care.
Studies have shown that integrated HCV and addiction treatment show an increase in patient
engagement in care (Batchelder et al., 2015; Burton et al., 2019; Butner et al., 2017; Treloar et
al., 2013) – further strengthening the presence of the HCV Clinic at MPHR. Meetings with the
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executive director, nursing director, and author began in late August of 2019 to discuss plans for
the HCV Clinic. These meetings culminated in a signed letter of support for the project from the
executive director of MPHR (Appendix C).
Looking ahead at sustainability – steps have already been taken for the author to become
credentialed to be able to bill for services pending negotiation of a WVU clinical faculty practice
site allowing the author (who is a WVU School of Nursing faculty) to continue the work.
The author has developed an HCV protocol checklist for other/new providers to follow
and will continue to revise and share this as needs arise (Appendix D). Opportunities for
expansion at MPHR include having a clinic that runs concurrent with the Wednesday harm
reduction time. They also have a mobile harm reduction unit that may have potential for reaching
other counties. Ideally, WV Medicaid would remove the current restrictions to treatment so that
primary care providers can treat all uncomplicated patients without referral to specialty
providers, paving the way for all providers at MPHR to become educated and confident to treat
HCV as an integral part of primary care. The author developed a policy brief to share with key
stakeholders at WV Medicaid with the intent to affect a change in policy that would remove
HCV treatment restrictions. In the long term, if the WHO (2017) goal of complete elimination by
2030 is met, the clinic would hopefully then become obsolete.
Impact Analysis
The primary expected impact will be an increase in the number of people with HCV who
are treated and cured of the disease. Integrating the HCV clinic with harm reduction services
means the clinic will have greater visibility to the population at highest risk for the disease. If
this pilot is successful and the model is imitated elsewhere, it could contribute significantly to the
WHO goal of worldwide elimination of HCV by 2030 (WHO, 2017). As much of what is written
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on a model where HCV care coincides with harm reduction services and/or addiction treatment
comes from abroad, there is opportunity to publish this work, as well as writing to inform other
healthcare providers with similar no-show rates of an innovative effective model of care to
implement in the US. It is said, “Success Breeds Success” – to those who are passionate about
bringing curative treatment to HCV patients and are in search of innovative ways to capture this
population, success of this pilot project may be attractive.
Resources
Personnel needs. Upon discussion with administrative personnel at MPHR prior to clinic
startup it was determined that the current staffing level for Friday afternoon was adequate to
manage any additional patient needs generated by the clinic, including check-in, rooming, and
lab draws. Clinic staff present on Friday afternoon includes an RN, LPN, two medical assistants,
and a receptionist. No additional personnel were required for clinic the function.
Budget. The total anticipated amount needed for this project was $3,275. At the time the
budget was developed, the author hoped to obtain a grant from the West Virginia Clinical &
Translational Science Institute (WVCTSI); however, the timing for grant submission/award did
not coincide with the project timing and the grant was not pursued. Funding for the project came
through donations. The actual cost of clinic implementation was $3038, which was $207 under
budget and $32 under the total income allotted for the project. The budget balance sheet with
explanations is presented in Appendix E.
Technology. MPHR has several laptop computers available for provider use to chart
using a web-based electronic health record (EHR). The author was named on the EHR license as
a provider at no additional cost to the organization. No further technology needs were identified
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during the pilot period, apart from the author’s laptop to track appointments using an Excel
spreadsheet and IBM SPSS software to calculate test statistics for project evaluation.
Congruence of Organization’s Strategic Plan/Mission to Project
Milan Puskar Health Right's Mission Statement:
Health Right is a primary care clinic that provides health care at no
cost to uninsured or underinsured low-income residents of North
Central WV. Health Right promotes health through direct service,
education, and advocacy.
The mission of MPHR aligns with the goals of this project well. Housed in MPHR is a syringe
access/harm reduction program known as the LIGHT program. LIGHT is an acronym for Living
In Good Health Together. Shared needles by PWID is the primary transmission route for HCV in
WV today (NVHR, 2017). Timing the HCV clinic to run concurrently with the LIGHT program
could minimize fear of stigma, promote patient trust, and improve access to care. MPHR
currently hosts several other specialty clinics such as women’s health, diabetes care, and HIV
testing, in addition to mental health services, homeless services, addiction treatment, and primary
health care. The founding premise of MPHR is that every person has a right to health care
regardless of their insurance status or ability to pay (GuideStar, 2017). The purpose of the project
is to increase the number of people cured of HCV in WV, and currently the population at greatest
risk is people who inject drugs – many of whom are either uninsured or underinsured. The
project is also in line with WVU’s mission, vision, and values of service to the community and
state as a land-grant institution.
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Evidence of Key Site Support
A letter of support was obtained by the director of MPHR and is included as an appendix
item as noted previously. Positive, welcoming attitudes and helpfulness of the staff at MPHR
were also evidence of their support for integrating the HCV Clinic.
Measurable Project Objectives
The overarching goal of the project is to increase patient engagement in care for HCV. To
that end, the three aims to evaluate this project were to 1) establish an integrated HCV clinic at a
MPHR to run concurrently with their LIGHT program on Friday afternoons, 2) evaluate the
efficacy of the plan, and 3) explore the reasons patients miss appointments.
Aim 1. Establishment of the HCV clinic at MPHR was measured through three
objectives. First, completing a checklist of items to carry out for the creation of the clinic. The
checklist was kept simple and is found in Appendix F. All checklist items were developed to
ease assimilation of the clinic into the current workflow. Each was accomplished prior to the first
patient care day. Second, a “Lunch and Learn” educational program, attended by a mix of
APRNs, RNs, MAs, social workers, counselors, and office staff, took place two days prior to the
first clinic day was evaluated using a pre/post-test (Appendix G) taken by all 15 attendees prior
to and following the program. An anonymous staff satisfaction evaluation survey (Appendix H)
was also used to evaluate the program. Using IBM SPSS, a paired-samples t-test was planned to
evaluate the impact of the educational presentation on staff knowledge of HCV care and
services.
A third objective, concerning implementation/feasibility, was added later to the pilot with
an IRB amendment to enhance the evaluation of clinic startup. An anonymous survey (Appendix
I) was administered via Qualtrics near the end of the 12-week pilot period to assess MPHR staff
perception of the value, need for, and rollout of the clinic. Development of the survey was
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guided by Bowen et al. (2009) where eight areas of focus for feasibility studies were identified.
The areas this survey focused on were acceptability – evaluated by satisfaction and intent to
continue use, demand – evaluated by fit within the organizational culture, implementation –
measured by degree and success or failure of execution, practicality – measured by the efficiency
and quality of implementation, integration – measured by the perceived fit with existing
infrastructure and perceived sustainability, expansion – measured by fit with organization goals
and culture and/or positive or negative effects on organization, , and limited efficacy – measured
by maintenance of changes from initial change.
Finally, clinic startup was evaluated periodically using the Plan-Do-Study-Act (PDSA)
method as described by the Institute for Healthcare Improvement (IHI, 2020). PDSA cycles have
been developed as a methodical system for making and evaluating changes on a small scale
(IHI). PDSA cycles directed improvements over the course of the project (IHI).
Aim 2. The planned evaluation of efficacy of the intervention to increase engagement in
HCV care was to maintain a deidentified Excel log (Appendix B) of appointments made, kept,
called to cancel, called to reschedule, or no-call/no-show and compare findings of no-call, noshow rates at two other clinics in Morgantown (one hospital-based, one located at a health
department).
Aim 3. The third aim was to discover reasons for the lack of engagement in care among
HCV patients using a Likert survey style questionnaire (Appendix A) with a list of 15 possible
reasons for missed appointments such as transportation problems, forgot, fear, dissatisfaction
with previous care/treatment to value on a scale of 1-5 how significant the items were with 1 =
Not at all and 5 = A lot. A text option was included to write in reasons not listed. There was also
a free text question to elicit what, if anything, the healthcare system could do to help them keep
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their appointments. Descriptive statistics were planned to reveal if a trend toward any reason/s
existed. Such information could then be used to explore ways to mitigate appointment barriers.
Any demographic data obtained would enrich the main project findings.
Results
Aim 1. The clinic startup checklist of items to accomplish prior to the first patient day
helped ensure that the staff and provider were prepared with the proper paperwork, supplies,
equipment, credentialing, and general readiness. The objective of increasing staff knowledge
about HCV was met through the educational “Lunch and Learn” program. Providing a light
lunch for participants helped create a warm learning environment. There was a significant
increase in the Staff Education test scores from pre-test (M = 5.13, SD = 1.13) to the post-test (M
= 6.67, SD = 0.62), t (14) = -5.996, p=<.001 (two-tailed). The mean change in scores was -1.53
with a 95% confidence interval ranging from [-2.08 to -.98]. The four-question Likert survey
designed to evaluate staff readiness and confidence was completed by 11(73%) attendees. The
scale ranged from 1 = Very satisfied to 5 = Very dissatisfied. For item 1 – The educational
program helped me feel prepared for this clinic – the mean score was 1.09 (SD = .302), for item
2 – The Phone Triage flyer helped me answer questions when patients called – the mean was
1.09 (SD = .302), the third item – The education program helped me feel more confident about
using patient assistance programs for HCV medications – had a mean of 1.18 (SD = .405), and
the final item – The learning objectives (disease process, fielding phone questions, anticipated
lab and imaging tests, and assistance programs) were met – had a mean of 1.09 (SD .302).
There were 13 respondents (n =13) to the implementation/feasibility survey including 11
females and two males with the average age range 35 to 45 years old. Sixty-two percent (62%)
of the respondents had worked at MPHR for less than two years, 23% 2-4 years, and 15% longer
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than six years with 85% of the respondents being full time employees and 15% part-time. The
participants were a mix of nursing staff, office staff, providers (MD, PA, NP), case
managers/social workers, and “others”. Ten (80%) of the 13 attended the prestart “Lunch and
Learn” session. The remaining items were based on a Likert scale of 1 = Strongly agree, 2 =
Somewhat agree, 3 = Neither agree nor disagree, 4 = Somewhat disagree, 5 = Strongly disagree,
and a sixth option = Not applicable. The results shown in Table 1 indicate the staff’s perceived
need and support for clinic.
The Plan stage of the cycle (plan for change) led to clinic readiness for the first patient
day on January 17, 2020. In the Do stage, the clinic began seeing patients on a small scale with
one – two patients scheduled per clinic session. In the Study phase the author noted what worked
well and what did not regarding workflow and referral, which led to changes in lab testing
ordered by primary care providers who expressed some confusion about the algorithm for
testing. In the Act phase a new, clearer algorithm was developed and made available to all
MPHR providers by posting in the providers’ workroom. The author elicited provider feedback
over the next couple of weeks of clinic and all expressed satisfaction with the improved testing
algorithm. No other issues were identified with subsequent PDSA cycles.
Aim 2. Over the nine weeks that the clinic was able to see patients, seven were
scheduled, two patients were seen, two did not call/show for their appointments, one cancelled
by phone, two other patients were found to have cleared the virus spontaneously and were
notified by their primary care providers of this finding and were removed from the schedule for a
final n = 5. While this is a small sample, there is some evidence of efficacy in that there was only
a 40% No-call/No-show rate during this time as depicted in Figure 1 and Table 2. Weather
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affected the clinic throughout the winter, and the onset of the COVID-19 pandemic disrupted the
final weeks of the project.
Aim 3. Of the two patients seen in clinic, only one qualified to complete the
survey exploring reasons for missed appointments. The second patient had been seen by a
volunteer prior to IRB approval for the project and was there for treatment follow-up. However,
some of the answers on the survey collected support the reasons for establishing this clinic – a
score of 3 was assigned to “Felt judged or discriminated against” and 5 for “Fear”. Other
reasons included “Forgot” and “Copay was too high”, which were both scored a 4. Concerns
written in the “Other” box included the cost of the medication and concern that re-treatment
would not be an option if infected again. Although survey data was only available from one
patient, an “n of 1” in clinical care/quality improvement may be a useful starting place to begin
to understand complex issues affecting this challenging population.
Discussion and Recommendations
The theoretical frameworks of Diffusion of Innovations (Rogers, 2003) and Candidacy
(Tookey et al., 2014) supported this project well. While much is written about this model in the
UK and Australia, (Batchelder et al., 2015; Burton et al., 2019; Butner et al., 2017; Treloar et al.,
2013), there is little about it in the US. Adopting this care model and reproducing it in WV has
the potential to impact the broader US population as it moves toward elimination of HCV. The
Tookey group (2014) Candidacy framework guides providers to ask good questions and be
sensitive to the unique needs of the population at greatest risk for HCV – PWID. For example, an
older patient may have had treatment prior to the new DAAs and not be aware that there are new
drugs in pill form, taken once daily for eight to twelve weeks that have few side effects. That
patient may be reticent to begin treatment based on past experience and lack of knowledge – they
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may be resistant to services (the last stage of Candidacy). Sensitive providers can overcome the
resistance with education and counseling to guide patients toward readiness for treatment.
The post-test analysis showed a significant increase in staff knowledge about HCV and
the functions of the clinic over the pretest; however, they may have benefited from further
discussion of the disease progression, and more in-depth discussion of a testing to treatment
algorithm – particularly for care providers as there were lingering questions about what labs to
order and when. It might have been better to hold two sessions – one for clinical staff and one for
providers as each group had discreet questions and needs. The PDSA cycle revealed the lab
testing algorithm issue so it could be remedied quickly.
As previously noted, weather and the onset of the COVID-19 may have been a factor in
patient referrals and appointments as MPHR was shifting to seeing only urgent needs patients
(which would not typically include HCV patients). Further impacting the case load was that a
few more patients that providers had planned to refer were found to have spontaneously cleared
the virus when lab tests in preparation for referral was obtained, so there was no need to refer.
Despite this, the no-call/no-show rate was shown at 9 weeks of clinic to be 40% (as previously
discussed, see Table 2 and Figure 1).
Another possible barrier for this clinic is the time frame. The clinic is only held once per
week on Friday afternoons, which could conflict with work or other schedules. Expanding to
include other appointment options may help increase attendance. The LIGHT harm reduction
program has a mobile unit that serves other counties which may have potential for screening and
HCV clinic referral. Another option might be to make the clinic schedule flexible – meaning that
the clinic is open from 1-4:30, and HCV patients can come at the time most convenient for them.
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The mobile unit and flex scheduling options are novel approaches that were not noted in the
literature reviewed for the project.
The project should be continued (in fact, there was concern expressed by staff about what
was to happen to the clinic at the end of the pilot), becoming part of the clinic standard of care
for PWID who also have HCV. MPHR providers see patients with HCV often. Establishing a
trusted presence is key to growing the clinic. Key stakeholders in the clinic – the director, staff,
providers – have expressed verbally and by survey responses that they believe in the value of an
HCV clinic on site. The clinic holds potential for further study to hone in on reasons this
population tends to have a high no-call/no-show rate, as well as demonstrate the efficacy of an
integrated clinical model of care by the volume of patients over a longer period. MPHR is well
suited for continuation and should serve WV well as a model for HCV care.
Conclusion
Although the clinic startup was successful, and staff HCV knowledge improved, clinic
attendance was minimal and additional reasons for lack of patient engagement remain unknown.
With time to establish a trusted presence with the patient population, warmer weather, abatement
of COVID-19, and increasing referrals from the MPHR primary care providers, the integrated
model of HCV care there has the potential to set the pace for similar models across the state. The
clinic is poised to explore and improve care engagement in hopes of halting WV’s and the
nation’s rising HCV transmission rate.
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Attainment of the Essentials of Doctoral Education for Advanced Practice
The eight Essentials of Doctoral Education for Advanced Practice are specified learning
outcomes and objectives put forth for DNP students by the American Association of Colleges of
Nursing (ANCC, 2006).
Essential I: Scientific Underpinnings for Practice was met using two theoretical frameworks
to support the clinic integration and qualitative research to explore reasons for lack of
engagement in care among PWID who have HCV.
Essential II: Organizational and Systems Leadership for Quality Improvement and
Systems Thinking objectives were met through the development and implementation of this
project - a care delivery approach was found lacking, but, through communication with Health
Right leadership, a plan to improve delivery of health care to hep c patients was developed. The
project required a feasibility and needs assessment study and the development of a budget.
Finally, the project demonstrates sensitivity to an organizational culture that is already sensitive
to the targeted population.
Essential III: Clinical Scholarship and Analytical Methods for Evidence-Based Practice
were met through performing a literature review and using the information to support a systems
change in the way the needs of HCV patients are met. The creation and implementation of a
qualitative interview/survey to explore the reasons for missed appointments in this population, a
quantitative data analysis of appointment no-call, no-shows compared to two other area Hep C
clinics, and dissemination of these findings through project presentation and publication will
complete this DNP essential.
Essential IV: Information Systems/Technology and Patient Care Technology for the
Improvement and Transformation of Health Care is met through the use of an excel spreadsheet

INTEGRATING CARE

26

to track appointments made and kept or not kept for analysis, as well as the use of statistical
software (IBM SPSS) to assist in that analysis to demonstrate significance.
Essential V: Health Care Policy for Advocacy in Health Care was met through the
preparation and presentation of a health policy brief poster on the cost of Hep C at the WV Nurse
Policy Day in Charleston, WV in 2019, and by presenting the project in poster form at the 2020
Nurse Policy Day.
Essential VI: Interprofessional Collaboration for Improving Patient and Population Health
Outcomes is being met through interprofessional collaborations with HCV experts (infectious
disease expert NPs and physicians), social workers attuned to the unique needs of this
population, and others through personal communication, online interaction via Project ECHO
(Expanding Capacity for Health Outcomes), and participation in the West Virginia Hepatitis
Academic Partners (WVHAMP) project as both a presenter and participant to advance primary
care providers as expert (and unrestricted) HCV treatment prescribers.
Essential VII: Clinical Prevention and Population Health for Improving the Nation’s
Health is met through integrating a Hep C clinic to coincide with a harm reduction program with
the intent of promoting engagement in care for hep C which will increase the number of persons
cured of this disease and reduce the risk of transmission.
Essential VIII: Advanced Nursing Practice was met through creating new patient and
professional relationships that promoted placement of the integrated clinic to improve patient
outcomes. Establishing this clinic required thinking at a higher level in order to develop the
protocols and systems that make the clinic function in a way that best meets the needs of the
patients and organization.
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Table 1.
Implementation/Feasibility Survey Results

Descriptive statistics
n
13

Minimum
1

Maximum
1

Mean
1.00

Std.
Deviation
0.000

13

1

1

1.00

0.000

13

4

6

5.00

0.408

The transition to having an HCV
clinic located at MPHR has been a
smooth one

13

1

3

1.46

0.660

There is no need for an HCV clinic at
MPHR

13

5

5

5.00

0.000

The HCV clinic is an added burden to
the staff

13

3

6

4.85

0.689

I have or plan to refer patients to the
HCV clinic at MPHR

13

1

6

1.54

1.450

The education program provided
before the HCV clinic opened helped
me understand the need for it at
MPHR
The HCV clinic has increased
congestion in the waiting room

13

1

6

2.77

2.315

13

3

6

4.92

0.641

The HCV clinic is valuable to MPHR

13

1

2

1.08

0.277

The education program provided
before the HCV clinic opened helped
prepare me for my role

15

1

6

3.13

2.200

The HCV clinic fits well with the
mission of MPHR
There is a need for an HCV clinic at
MPHR
The HCV clinic at MPHR interferes
with other services offered here
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Table 2.
Percent of No-call/No-show

Frequency
Valid

Percent

Valid

Cumulative

Percent

Percent

Yes

2

40.0

40.0

40.0

No

3

60.0

60.0

100.0

Total

5

100.0

100.0
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Figure 1.
Percent of No-call/No-show
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Appendix A

Hepatitis C Clinic at Milan Puskar Health Right Interview Questionnaire Survey Tool
Patient age:

Gender (Circle one)

Male

Marital status (Circle one)

M

Female
S

W

D

Length of time since you were first diagnosed with Hep C?
Employed

Yes

No

1. Have you ever been referred to a Hepatitis C clinic in the past?

Yes

No

2. If so, did you make that appointment?

Yes

No

3. If you made an appointment, did you keep it?

Yes

No

4. Below is a list of possible reasons you did not make or were not able to go to your appointment.
For each problem listed please indicate on a scale of 1-5 how significant that was to missing your
appointment. 1=Not at all; 2=a little; 3=moderately; 4=more; 5=a lot
Transportation problems

1

2

3

4

5

Forgot

1

2

3

4

5

No insurance

1

2

3

4

5

Copay was too high

1

2

3

4

5

Insurance problems

1

2

3

4

5

Sick on day of appointment

1

2

3

4

5

Fear

1

2

3

4

5

Childcare problems

1

2

3

4

5

Work

1

2

3

4

5

School

1

2

3

4

5

Thought it was a waste of time

1

2

3

4

5

Not satisfied with previous care/treatment

1

2

3

4

5

Language or accessibility needs not met

1

2

3

4

5

You heard from someone else there was nothing that could be done?

1

2

3

4

5

Felt judged or discriminated against

1

2

3

4

5

Other:
5. What, if anything, could the healthcare system do to help you keep appointment/s at this clinic
and any others you may have missed appointments at?
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Hep C Clinic at Milan Puskar Health Right Log of Appointment Responses
Name (Delete name upon log entry of
Appt Date/Time
appointment outcome)

Deleted
Deleted

Appt
Kept

1/17/2020

Called
to
cancel

Called to
reschedule

Nocall/Noshow

x

2/14/2020

x

Deleted

2/14/2020

x

Deleted

2/21/2020

x

Deleted

2/28/2020 x

Deleted
Deleted

3/6/2020
3/13/2020 x

x
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HCV Patient Labs/Studies Checklist
Note: This is a list of what is standard for new HCV patient evaluation (it’s the checklist I use).
With the removal of the liver fibrosis restriction imposed by Medicaid, we usually will not need a
Fibrosure test or ultrasound, unless the patient has RUQ pain, jaundice, significantly elevated
liver enzymes, or other s/s of liver damage.

1. Confirm infection status with PCR RNA Quantitative with reflex to genotype

Once infection status is confirmed – IF patient is being seen by PCP and getting
labs prior to HCV Clinic, it would be great if these could be included. Otherwise,
I will order at time of visit.
2. Other pre-treatment labs (lipids and Fibrosure are 8-hour fasting labs):
a. CBC/diff
b. BUN/Cr
c. AST, ALT, Alk phos
d. Iron, Transferrin, Ferritin, and TIBC
e. Total and calculated bili
f. Albumin
g. PTT, PT/INR (Check with Emily)
h. Vitamin D
i. HCV Genotype (if not already done)
j. Liver Fibrosis (Fibrosure) Ask – may not be necessary for all patients
Ruby: 1237128 (8 hour fasting)
Mon Gen (LabCorp): 550123 (8 hour fasting)
k. Anti-Hep A IGG, Hep A IgM Ab
l. Hep B Surface Ab, Hep B surface antigen, Hep B total core Ab (Anti-HBc) – this
is important to confirm no active Hep B infection – HCV treatment can cause a
flareup of symptoms
m. A1C
n. Consider lipid panel
3. Imaging – Elastography (CPT = 91200) OR RUQ US (CPT = 76705) as needed
4. PHQ9 Patient Health Questionnaire tool for depression
5. Assess for and immunize as appropriate for:
a. Hep A
b. Hep B
c. Pneumovax
d. Tdap
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Appendix E

Budget
Clinic Items

Projected Cost

Administrative: Nurse Practitioner (Project Coordinator) time =
$50/hr x 4hrs/week x 12 weeks = $2400 clinical time, $50/hour
x 10 hours for preparation of materials, staff education
Support staff cost absorbed by organization (no additional staff
required at this time)

Actual
Cost

Difference

$2900

$2900

$0

Educational Materials (Flyers for patients, Ppt handouts for
staff, CE/certificate)

$50

$10

+$40

Project supplies (Office supplies, copy paper)

$25

$10

+$15

$0

$0

$0

$150

$123

+$27

$0

$0

$0

$100

$25

+$75

$50

$0

+$50

$0

$0

$0

$3,275

$3068

+$207

Facilities (Contributed by organization)
Hospitality (Lunch for 10 staff on education day X $15/pp)
Travel (N/A – travel is within author’s normal driving distance)
Incentive (small token for questionnaire completion by known
HCV positive patients - $2/each for 50 questionnaires)
Unanticipated expenses
Marketing (Flyers to post in clinic-cost covered under supplies)
Total

Projected Income Source
WVCTSI Small Grant
Personal funds
Other

Amount

•

$5,000
$200

•

$0

•

Total projected income

$5,200

Total actual income

$3100

Total actual cost

Additional budget comments:

- $3068
+$32

•

•

MPHR is funded by grants and donations. Hourly wage based
on the US Bureau of Labor and Statistics average NP wage for
West Virginia (U.S. Bureau of Labor Statistics, 2018)
Patient gifts were purchased as appreciation for completing a
questionnaire.
Facilities are already operational with all necessary equipment
and software. Student will use personal computer equipped
with Excel to create and maintain deidentified tracking log
This location already has clinics servicing patients, a
concurrent 4-hour clinic should not add an undue burden to
current staff
Met with WVCTSI staff member on 7/16/19 – was encouraged
to apply for a grant; however, the time frame to apply for a
grant to use in the projected time frame for this project had
passed. Time and money donated by author kept cost within
budget.
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Milan Puskar Health Right Hepatitis C Clinic – Getting started checklist

Meet with key leaders and sign agreement with Milan Puskar Health Right
Start credentialing with MPHR
Copy of malpractice insurance from Toni Dichiacchio
CAQH ProView Updated and attested
Notify WVBON - Prescribing
Education/in-service with MPHR staff
Review paperwork – checklists, phone triage, intake form
DNP Student to orient to MPHR EHR System
DNP Student to orient to workflow at MPHR
Set up exam room (exam table, chair, otoscope, reflex hammer, tongue blades)
Set up desk space (office supplies as needed)

= Completed prior to January 17, 2020 – the first day of clinic
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Appendix G
Staff Education Pre and Post Test

1. Hepatitis C is a systemic disease?

True

False

True

False

2. A DAA is:
a. A direct acting antiviral
b. A direct antiviral agent
c. A decreased antiviral account
d. None of the above
3. Drug manufacturers do not provide medications to needy patients.

4. When patients call to ask questions about the Hepatitis C/clinic I should....
a. Tell them, “I can’t answer any questions” and they should just make an appointment
b. Refer to the Phone Triage form to find answers to the most common questions
c. Tell the patient I don’t know the answer but I can find out and get back to them
d. b and c
5. The new patient intake questionnairea. is for patients who already come to Milan Puskar Health Right for their primary care
b. is for all patients who are being seen in the Hepatitis C clinic for the first time
c. does not need completed if patient is already established at Milan Puskar Health Right
d. must be completed by a nurse
6. Medicaid does not cover treatment for Hepatitis C
7. Prior authorization can be obtained by – select all that apply
a. a nurse practitioner
b. a medical assistant (MA)
c. an LPN
d. specialty pharmacy
e. all of the above

True

False
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Staff Satisfaction Questionnaire (Anonymous)
Please circle your response:
1=Very satisfied 2=Satisfied 3=Neutral 4=Dissatisfied 5=Very dissatisfied

The educational program helped me feel prepared for this clinic.

The Phone Triage flyer helped me answer questions when patients called.

1 2 3 4 5

1 2 3 4 5

The education program helped me feel more confident about using patient
assistance programs for HCV medications

1 2 3 4 5

The learning objectives (disease process, fielding phone question, anticipated
lab and imaging tests, assistance programs) were met

1 2 3 4 5

Comments:

What would improve your confidence in managing HCV patients at MPHR?
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Hepatitis C Clinic at Milan Puskar Health Right Implementation/Feasibility Survey Tool
Demographic information:
Gender(Circle one) Male Female Prefer not to answer

Age:__________Years

Length of time employed at Health Right (if paid employee):

__________Years

Employment status:

Full time

Part time

Volunteer at Health Right

Number of hours/week___________

Role/position at Health Right (Nurse, provider, case manager, etc…)
Did you attend the Lunch and Learn educational program in January?

________________________
Yes

No

Please rate your response to each question on the topic of having a hepatitis C (HCV) clinic located at
Milan Puskar Health Right (MPHR) using the following scale:
1=Strongly Disagree; 2=Disagree; 3=Neutral; 4=Agree; 5=Strongly Agree
The HCV clinic fits well with the mission of MPHR
N/A 1

2

3

4

5

There is a need for an HCV clinic at MPHR

N/A 1

2

3

4

5

The HCV clinic at MPHR interferes with other services offered here
The transition to having an HCV clinic located at MPHR has been a
smooth one
There is no need for an HCV clinic at MPHR

N/A 1

2

3

4

5

N/A 1

2

3

4

5

N/A 1

2

3

4

5

The HCV clinic is an added burden to the staff

N/A 1
N/A 1

2
2

3
3

4
4

5
5

N/A 1

2

3

4

5

The education program provided before the HCV clinic opened helped
me understand the need for it at MPHR

N/A 1

2

3

4

5

The HCV clinic increased congestion in the waiting room

N/A 1

2

3

4

5

The HCV clinic is valuable to MPHR

N/A 1

2

3

4

5

The education program provided before the HCV clinic opened helped
prepare me for my role
Other suggestions or comments:

N/A 1

2

3

4

5

I understand the process of referring to the HCV clinic at MPHR
I have or plan to refer patients to the HCV clinic at MPHR
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From: Danielle Ludwig <dani.ludwig.light@gmail.com>
Sent: Friday, April 10, 2020 1:54 PM
To: McKenrick, Susan <susan.mckenrick@hsc.wvu.edu>
Subject: Re: Question for you

Just reading that made my heart melt and tears to my eyes! You just don’t know how
grateful I am for you! Thanks for adding me to your project! The love I have for you is
unconditional and true.
Much love my dear friend,
Dani
On Thu, Apr 9, 2020 at 5:48 PM McKenrick, Susan <susan.mckenrick@hsc.wvu.edu>
wrote:
Hi Dani,
I will be presenting my DNP project next week and I am finally finishing up my paper. Below is
my acknowledgment page - I wanted to share it with you and make sure you are OK with your
name being in it.
Hugs,
Sue
Susan R. McKenrick, MSN, APRN, FNP-BC, DNP2B
Clinical Assistant Professor
WVU School of Nursing
6600 Health Sciences Center
Post Office Box 9600
Morgantown, WV 26506-9602
susan.mckenrick@hsc.wvu.edu

